- The report assesses Myocardial Ischemia therapeutics based on drug target , mechanism of action ( MoA ), route of administration ( RoA ) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia
Reasons To Buy - Gain strategically significant competitor information , analysis , and insights to formulate effective R & D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it ' s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Buy a Sample Copy of This Report @ http :// www . radiantinsights . com / research / myocardial-ischemia-pipelinereview-h2-2016 / request-sample
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Myocardial Ischemia Overview 8 Therapeutics Development 9 Pipeline Products for Myocardial Ischemia - Overview 9 Pipeline Products for Myocardial Ischemia - Comparative Analysis 10 Myocardial Ischemia - Therapeutics under Development by Companies 11 Myocardial Ischemia - Therapeutics under Investigation by Universities / Institutes 12 Myocardial Ischemia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Myocardial Ischemia - Products under Development by Companies 16 Myocardial Ischemia - Products under Investigation by Universities / Institutes 17 Myocardial Ischemia - Companies Involved in Therapeutics Development 18 Bayer AG 18 Cellmid Limited 19 CohBar , Inc . 20 Lixte Biotechnology Holdings , Inc . 21 Miltenyi Biotec GmbH 22 NoNO , Inc . 23 Shire Plc 24 Symic Biomedical , Inc . 25 Taxus Cardium Pharmaceuticals Group Inc . 26 ViroMed Co ., Ltd . 27 Myocardial Ischemia - Therapeutics Assessment 28